This company listing is no longer active
HeiQ Valuation
Is 9JC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9JC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 9JC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 9JC's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9JC?
Key metric: As 9JC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 9JC's PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | US$41.55m |
| Market Cap | US$9.61m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.6x |
| Enterprise Value/EBITDA | -2.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 9JC's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
BIG1 Bio-Gate | 0.8x | 16.3% | €6.5m |
BNN BRAIN Biotech | 1.3x | 8.5% | €71.4m |
NTG Nabaltec | 0.6x | 5.0% | €123.2m |
2HRA H&R GmbH KGaA | 0.1x | 3.0% | €129.2m |
9JC HeiQ | 0.2x | n/a | €7.6m |
Price-To-Sales vs Peers: 9JC is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does 9JC's PS Ratio compare vs other companies in the European Chemicals Industry?
Price-To-Sales vs Industry: 9JC is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is 9JC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 9JC's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Arkema
€5.7b
Manufactures and sells specialty chemicals and advanced materials worldwide.
V1S
€74.85
7D
0.4%
1Y
-19.9%
Minerals Technologies
US$2.6b
Develops, produces, and markets various mineral, mineral-based, and related systems and services.
MNK
US$74.50
7D
1.4%
1Y
33.0%
Mitsubishi Chemical Group
JP¥1.1t
Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.
M3C
JP¥4.77
7D
-4.3%
1Y
-20.5%